Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1996;93:153-160

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biemond, B. J.
Right arrow Articles by ten Cate, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biemond, B. J.
Right arrow Articles by ten Cate, J. W.

(Circulation. 1996;93:153-160.)
© 1996 American Heart Association, Inc.


Articles

Comparison of Sustained Antithrombotic Effects of Inhibitors of Thrombin and Factor Xa in Experimental Thrombosis

Bart J. Biemond, MD; Philip W. Friederich, MD; Marcel Levi, MD; George P. Vlasuk, PhD; Harry R. Büller, MD; Jan W. ten Cate, MD

From the Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research (B.J.B., P.W.F., M.L., H.R.B., J.W.t.C.), Academic Medical Center, University of Amsterdam, Netherlands; and Corvas International Inc (G.P.V.), San Diego, Calif.

Correspondence to Bart J. Biemond, MD, Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.

Background In the pathogenesis of (recurrent) thrombosis, clot-associated thrombin appears to play an important role. Antithrombin III–independent thrombin inhibitors have been shown to neutralize clot-bound thrombin effectively. We compared the sustained antithrombotic effects and the effects on endogenous fibrinolysis of several of these agents with recombinant tick anticoagulant peptide (rTAP), a selective factor Xa inhibitor, and low-molecular-weight heparin (LMWH) in an experimental venous thrombosis model.

Methods and Results Rabbits received either recombinant hirudin (rHir), Hirulog-1, CVS#995 (a novel direct inhibitor of thrombin), rTAP, LMWH, or saline. The effect on thrombus growth was assessed by measuring the accretion of 125I-labeled fibrinogen onto preformed nonradioactive thrombi, and the effect on endogenous fibrinolysis was assessed by measuring the decline in radioactivity of preformed 125I-labeled thrombi in rabbit jugular veins. All direct thrombin inhibitors induced a sustained antithrombotic effect compared with either LMWH and rTAP. In addition, CVS#995 also further decreased thrombus size after stopping its infusion, which was due to a significant enhancement of endogenous fibrinolysis.

Conclusions Direct thrombin inhibition by rHir, Hirulog-1, or CVS#995 induces a sustained antithrombotic effect compared with rTAP and LMWH, which is most likely due to inhibition of clot-bound thrombin. CVS#995 was shown to also enhance the extent of endogenous fibrinolysis to a greater degree compared with rHir and might therefore be an interesting new antithrombotic agent for the treatment of venous and arterial thrombosis.


Key Words: anticoagulants • thrombosis • fibrinolysis




This article has been cited by other articles:


Home page
CLIN APPL THROMB HEMOSTHome page
J. M. Wilson, J. Gilbert, M. Harlan, A. Bracey, P. Allison, C. Schooley, and K. Pinto
High-dose Intravenous Dalteparin Can be Monitored Effectively Using Standard Coagulation Times
Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 127 - 138.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. M. Bates and J. I. Weitz
Emerging Anticoagulant Drugs
Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1491 - 1500.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
U. Rauch, J. I. Osende, V. Fuster, J. J. Badimon, Z. Fayad, and J. H. Chesebro
Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences
Ann Intern Med, February 6, 2001; 134(3): 224 - 238.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. M. Camire, M. Kalafatis, P. Simioni, A. Girolami, and P. B. Tracy
Platelet-Derived Factor Va/VaLeiden Cofactor Activities Are Sustained on the Surface of Activated Platelets Despite the Presence of Activated Protein C
Blood, April 15, 1998; 91(8): 2818 - 2829.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. J. Meyer, J. J. Badimon, J. H. Chesebro, J. T. Fallon, V. Fuster, and L. Badimon
Dissolution of Mural Thrombus by Specific Thrombin Inhibition With r-Hirudin : Comparison With Heparin and Aspirin
Circulation, February 24, 1998; 97(7): 681 - 685.
[Abstract] [Full Text] [PDF]